Neutropenia in tumor patients
Conditions
Interventions
experimental group:The efficacy and risk control of primary prevention of neutropenia or FN caused by anti-tumor therapy in solid tumors with Mecapegfilgrastim Injection
control group:Do not take any action
Sponsors
Anqing First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Solid tumors diagnosed by pathological histology or cytology; (2) Age over 18 years; (3) The patient's treatment regimen must include moderately risk chemotherapy drugs (see Table 1); (4) Expected survival greater than 3 months; (5) Patient's informed consent.
Exclusion criteria
Exclusion criteria: (1) Acute inflammatory activity phase (tuberculosis, septic shock, sepsis, etc.); (2) All antitumor drugs are not included in the acceptable regimen (Table 1); (3) Uncontrolled severe chronic liver or kidney disease (creatinine >1.5× upper limit of normal; aspartate aminotransferase and alanine aminotransferase 2× upper limit of normal); (4) Severe comorbidities: including COPD respiratory failure, heart failure (NYHA III-IV); (5) Patients with unstable respiratory or circulatory conditions requiring emergency intervention; (6) Use of drugs affecting white blood cell count within the past 2 weeks: vancomycin, chloramphenicol, methimazole, etc.; (7) Acute myeloid leukemia, myelodysplastic syndrome, chronic aplastic anemia, hematopoietic stem cell transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and duration of neutropenia at 3/4 degrees; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of neutropenic fever (FN);The usage rate of antibiotics;Incidence of delayed chemotherapy and dose reduction; | — |
Countries
China
Contacts
Public ContactHao Jiang
Anqing First People's Hospital
Outcome results
None listed